[1]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clini-cians, 72, 7-33. https://doi.org/10.3322/caac.21708
|
[2]
|
Okunade, K.S. (2020) Human Papillomavirus and Cervi-cal Cancer. Journal of Obstetrics and Gynaecology, 40, 602-608. https://doi.org/10.1080/01443615.2019.1634030
|
[3]
|
Murillo, R. and Ordóñez-Reyes, C. (2019) Human Papillo-mavirus (HPV) Vaccination: From Clinical Studies to Immunization Programs. International Journal of Gynecological Cancer, 29, 1317-1326.
https://doi.org/10.1136/ijgc-2019-000582
|
[4]
|
Soto, D., Song, C. and Mclaughlin-Drubin, M.E. (2017) Epigenetic Alterations in Human Papillomavirus-Associated Cancers. Viruses, 9, Article No. 248. https://doi.org/10.3390/v9090248
|
[5]
|
Wherry, E.J. and Kurachi, M. (2015) Molecular and Cellular Insights into T Cell Exhaustion. Nature Reviews Immunology, 15, 486-499. https://doi.org/10.1038/nri3862
|
[6]
|
Shaikh, M.H., Bortnik, V., Mcmillan, N.A. and Idris, A. (2019) cGAS-STING Responses Are Dampened in High-Risk HPV Type 16 Positive Head and Neck Squamous Cell Carcinoma Cells. Microbial Pathogenesis, 132, 162-165.
https://doi.org/10.1016/j.micpath.2019.05.004
|
[7]
|
Ronco, L.V., Karpova, A.Y., Vidal, M. and Howley, P.M. (1998) Human Papillomavirus 16 E6 Oncoprotein Binds to Interferon Regulatory Factor-3 and Inhibits Its Transcription-al Activity. Genes & Development, 12, 2061-2072.
https://doi.org/10.1101/gad.12.13.2061
|
[8]
|
Crusz, S.M. and Miller, R.E. (2020) Targeted Therapies in Gynaeco-logical Cancers. Histopathology, 76, 157-170.
https://doi.org/10.1111/his.14009
|
[9]
|
Hemmat, N. and Baghi, H.B. (2018) Human Papillomavirus E5 Protein, the Undercover Culprit of Tumorigenesis. Infectious Agents and Cancer, 13, Article No. 31. https://doi.org/10.1186/s13027-018-0208-3
|
[10]
|
Li, X., Wang, R., Fan, P., Yao, X., Qin, L., Peng, Y., et al. (2019) A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. Frontiers in Oncology, 9, Article No. 1066. https://doi.org/10.3389/fonc.2019.01066
|
[11]
|
Dai, S., Zeng, H., Liu, Z., Jin, K., Jiang, W., Wang, Z., et al. (2021) Intratumoral CXCL13(+)CD8(+)T Cell Infiltration Determines Poor Clinical Outcomes and Immunoevasive Contexture in Patients with Clear Cell Renal Cell Carcinoma. The Journal for ImmunoTherapy of Cancer, 9, e001823. https://doi.org/10.1136/jitc-2020-001823
|
[12]
|
Wu, Y., Chen, W., Xu, Z.P. and Gu, W. (2019) PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or In-hibition. Frontiers in Immunology, 10, Article No. 2022.
https://doi.org/10.3389/fimmu.2019.02022
|
[13]
|
Kraehenbuehl, L., Weng, C.H., Eghbali, S., Wolchok, J.D. and Merghoub, T. (2022) Enhancing Immunotherapy in Cancer by Targeting Emerging Immunomodulatory Pathways. Na-ture Reviews Clinical Oncology, 19, 37-50.
https://doi.org/10.1038/s41571-021-00552-7
|
[14]
|
Allouch, S., Malki, A., Allouch, A., Gupta, I., Vranic, S. and Al Moustafa, A.E. (2020) High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions. Frontiers in Oncology, 10, Article No. 914. https://doi.org/10.3389/fonc.2020.00914
|
[15]
|
Liu, C., Lu, J., Tian, H., Du, W., Zhao, L., Feng, J., Yuan, D. and Li, Z. (2017) Increased Expression of PD‑L1 by the Human Papillomavirus 16 E7 Oncoprotein Inhibits Anticancer Immun-ity. Molecular Medicine Reports, 15, 1063-1070.
https://doi.org/10.3892/mmr.2017.6102
|
[16]
|
Wang, Y., Wang, C., Qiu, J., Qu, X., Peng, J., Lu, C., Zhang, M., Zhang, M., Qi, X., Li, G. and Hua, K. (2022) Targeting CD96 Overcomes PD-1 Blockade Resistance by Enhancing CD8+ TIL Function in Cervical Cancer. The Journal for ImmunoTherapy of Cancer, 10, e003667. https://doi.org/10.1136/jitc-2021-003667
|
[17]
|
Podlesnykh, S.V., Abramova, K.E., Gordeeva, A., Khlebnikov, A.I. and Chapoval, A.I. (2021) Peptide Blocking CTLA-4 and B7-1 Interaction. Molecules, 26, 253. https://doi.org/10.3390/molecules26020253
|
[18]
|
Gao, H., Cai, H., Liu, J., Wang, X., Zheng, P., Devenport, M., Xu, T., Dou, F., Liu, Y. and Zhou, A. (2020) Structure of CTLA-4 Complexed with a pH-Sensitive Cancer Immuno-therapeutic Antibody. Cell Discovery, 6, Article No. 79.
https://doi.org/10.1038/s41421-020-00202-9
|
[19]
|
Tie, Y., Tang, F., Wei, Y.Q. and Wei, X.W. (2022) Immuno-suppressive Cells in Cancer: Mechanisms and Potential Therapeutic Targets. Journal of Hematology & Oncology, 15, Article No. 61.
https://doi.org/10.1186/s13045-022-01282-8
|
[20]
|
Monney, L., Sabatos, C.A., Gaglia, J.L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E.A., Coyle, A.J., Sobel, R.A., Freeman, G.J. and Kuchroo, V.K. (2002) Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease. Nature, 415, 536-541. https://doi.org/10.1038/415536a
|
[21]
|
Zhao, L., Cheng, S., Fan, L., Zhang, B. and Xu, S. (2021) TIM-3: An Update on Immunotherapy. International Immunopharmacology, 99, Article ID: 107933. https://doi.org/10.1016/j.intimp.2021.107933
|
[22]
|
Chen, Z., Dong, D., Zhu, Y., Pang, N. and Ding, J. (2021) The Role of Tim-3/Galectin-9 Pathway in T-Cell Function and Prognosis of Patients with Human Papilloma Virus-Associated Cervical Carcinoma. The FASEB Journal, 35, e21401. https://doi.org/10.1096/fj.202000528RR
|
[23]
|
Maiorano, B.A., Maiorano, M.F.P., Ciardiello, D., Maglione, A., Orditura, M., Lorusso, D. and Maiello, E. (2022) Beyond Plati-num, ICIs in Metastatic Cervical Cancer: A Systematic Review. Cancers (Basel), 14, Article No. 5955.
https://doi.org/10.3390/cancers14235955
|
[24]
|
Wu, X., Ji, J., Lou, H., Li, Y., Feng, M., Xu, N., Li, Y., et al. (2022) Efficacy and Safety of Cadonilimab, an Anti-PD-1/CTLA4 Bi-Specific Antibody, in Previously Treated Recurrent or Metastatic (R/M) Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase II Trial (075). Gynecologic Oncology, 166, S47-S48.
https://doi.org/ https://doi.org/10.1016/S0090-8258(22)01293-8
|
[25]
|
O’malley, D.M., Neffa, M., Monk, B.J., Melkadze, T., Huang, M., Kryzhanivska, A., et al. (2022) Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstili-mab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. Journal of Clinical Oncology, 40, 762-771.
https://doi.org/10.1200/jco.21.02067
|
[26]
|
Darnell, E.P., Mooradian, M.J., Baruch, E.N., Yilmaz, M. and Reynolds, K.L. (2020) Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Current Oncology Reports, 22, Article No. 39.
https://doi.org/10.1007/s11912-020-0897-9
|
[27]
|
Wang, M., Ma, X., Guo, L. and Xia, F. (2017) Safety and Effi-cacy Profile of Pembrolizumab in Solid Cancer: Pooled Reanalysis Based on Randomized Controlled Trials. Drug De-sign, Development and Therapy, 11, 2851-2860.
https://doi.org/10.2147/dddt.S146286
|